Navigation Links
Aurobindo Receives Approval from USFDA for anti-AIDS drug

AIDS patients, the world over, can heave a sigh of relief following the nod of approval from the US Food & Drug Administration// (FDA) for the world’s first anti-AIDS cocktail drug for use as a single dose.

The drug manufacturer, Hyderabad-based bulk drugs major Aurobindo Pharma, has made combined anti-retro virals (ARVs) — Retrovir (zidovudine), Epivir (lamivudine) and Viramune (nevirapine) into a single three-in-one fixed dose drug.

The World Health Organisation (WHO) recognizes the three drugs as the first line of therapy for AIDS and they constitute about 50% of drug therapy against the disease.

Therefore the combination of the three drugs as a single tablet will result in fewer dosages as well as side-effects making life much easier for patients. Otherwise these patients have to consume about 20-30 pills a day for the Highly Active Antiretroviral Therapy (HAART) in treating AIDS.

With the US FDA approval means the drug can be sold immediately in over 15 countries as part of the $15 billion US President’s Emergency Plan for AIDS Relief (PEPFAR) programme.

Besides this, since the combination drug has now become a new drug it can receive new drug approval (NDA) and sold in the US markets, once the patents on the individual components expire. The combined market for these three drugs is estimated at a whopping $5 billion annually in the US alone.

The patents for these drugs in the US market expire in 2009 and 2010.

According to Lanka Srinivas, director, Aurobindo Pharma, 'This is indeed a major milestone for Aurobindo and, in fact, the whole country. What is further significant is that this is the first triple combination filing approved by the US FDA and, in fact, the first one ever filed.'

Lanka added that Aurobindo is targeting over $100 million in total revenues from the export of ARVs next year from the current $60 million.

'"/>




Page: 1

Related medicine news :

1. Aurobindo gets U.S. FDA approval for Cephalexin
2. US FDA approved Aurobindo Pharma to produce generic AIDS drug
3. Aurobindo Gets Tentative USFDA Approval For Its HIV-1 Drug
4. Aurobindo Pharma Purchases US Manufacturing Facility
5. Aurobindo Gets USFDA Approval for Didanosine Chewable Tablets
6. Aurobindo Gets USFDA Approval for A 3-Drug Combination Pack
7. Fifth US Patient Receives Artificial Heart
8. Northfield Labs Receives FDA Comments
9. British MPs Say Prostate Cancer Receives Low Priority in the NHS
10. Abbott Receives CE Mark Certification
11. Zactima Receives Fast Track Designation By The FDA
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/20/2017)... Fla. (PRWEB) , ... February 20, 2017 , ... Scrubbing ... Cancer Center in Houston, Dr. Christopher Pezzi remembers the excitement of the surgeon training ... believe they pay us to do this? Don’t tell anyone, but I would do ...
(Date:2/20/2017)... ... February 20, 2017 , ... ... industries, announced Biscom Document Router (BDR), the first IoT device from Biscom designed ... and imaging. Biscom will debut BDR at HIMSS17 and will be ...
(Date:2/20/2017)... ... February 20, 2017 , ... Johns Hopkins All Children's Hospital celebrated a ... out ceremony on Friday marked the halfway point of construction and lifting of the ... 2018, will serve as a center for innovation aimed at finding new discoveries and ...
(Date:2/19/2017)... ... February 19, 2017 , ... Braun Industries will be participating as an ... event will take place February 23-25, 2017 at the Calvin L. Rampton Salt Palace ... with three new ambulances on display. , “JEMS is a leader ...
(Date:2/18/2017)... ... February 17, 2017 , ... ... disruptive innovation in the industry, according to the recent NEJM Catalyst Insights Report ... surveys of the NEJM Catalyst Insights Council, a qualified group of U.S. executives, ...
Breaking Medicine News(10 mins):
(Date:2/20/2017)... , Feb. 20, 2017 Systems ... that creates detailed images of the organs and tissues ... field and radio waves. The technique does not use ... of brain function or growth of cancer. MRI is ... neurology, cardiology, oncology, musculoskeletal, and orthopedics. Hence, MRI helps ...
(Date:2/20/2017)... -- Report analyzes the worldwide markets for Infusion ... Ambulatory Infusion Pumps, Enteral Feeding Pumps, Insulin Infusion ... and Syringe Infusion Pumps. The report provides separate ... Asia-Pacific, Latin America, and Rest of World. ... Annual estimates and forecasts are provided for ...
(Date:2/20/2017)... This report analyzes the worldwide markets for Human ... comprehensive analytics for the US, Canada , ... Asia-Pacific , and Rest of World. ... Annual estimates and forecasts are provided for the period ... for these markets. Market data and analytics are derived from ...
Breaking Medicine Technology: